BACTERIAL POLYSACCHARIDE CROSS-REACTIVE WITH MENINGOCOCCAL GROUP A POLYSACCHARIDE

与其他有包膜的细菌病原体类似，抗荚膜 多糖抗体赋予对奈瑟氏菌引起的疾病的免疫力 脑膜炎 A群脑膜炎球菌病有不同的流行病学 比其他致病血清型更强 在非洲，A组脑膜炎是 高频率的地方性;在世界其他地区，A组原因 流行病 在这两种情况下，A组无症状携带 脑膜炎双球菌低。 在美国，A组疾病或携带 脑膜炎球菌可以认为在过去30年中没有出现过。 然而，大多数 全世界的儿童和年轻人都有A组多糖 抗体的 在寻找交叉反应多糖的研究中， 在非致病性正常植物群中， “天然”免疫力，两种大肠杆菌荚膜多糖，K93和 K51的血清学特性和结构 表征了 尽管它们具有抗原交叉反应性，但K93和K51 未能从免疫前和免疫后的血清中吸收A组抗体， 接种A群脑膜炎球菌疫苗。 重要性 0-K93多糖中的乙酰基在这种交叉反应性中是 确立了习 K93、K51和A组多糖的合成方案 与医学上有用的载体蛋白质结合， 制备用于临床评价的缀合物。 这样的产品应该更多 婴幼儿A群脑膜炎有效免疫原研究 A组疫苗。 患者，无恶性肿瘤，单克隆抗体水平高 与B群脑膜炎球菌和E群脑膜炎球菌反应。大肠杆菌K1荚膜 多糖被发现。 的特异性和保护作用 对该单克隆抗体进行了表征。 其治疗效果在 计划研究B组脑膜炎球菌性脑膜炎的治疗。

Similar to other encapsulated bacterial pathogens, anti-capsular polysaccharide antibodies confer immunity to diseases caused by Neisseria meningitidis. Group A meningococcal diseases have a different epidemiology than the other pathogenic serogroups. In Africa, Group A meningitis is endemic with high frequency; in other parts of the world, Group A causes epidemics. In both situations, asymptomatic carriage of Group A meningococci is low. In the U.S., disease or carriage of Group A meningococci can be considered as absent for the past 30 years. Yet, most children and young adults throughout the world have Group A polysaccharide antibodies. During investigations to find cross-reactive polysaccharides among non-pathogenic normal flora that might account for this ubiquitous "natural" immunity, two Escherichia coli capsular polysaccharides, K93 and K51, were discovered and their serological properties and structures characterized. Despite their antigenic cross-reactivity, the K93 and K51 failed to absorb Group A antibodies from pre and post immunization sera of vaccinates injected with Group A meningococcal vaccine. Importance of the 0-acetyl in the K93 polysaccharide in this cross-reactivity was established. Schemes for synthesis of K93, K51 and Group A polysaccharides with medically useful carrier proteins have been devised in order to prepare conjugates for clinical evaluation. Such products should be more effective immunogens against Group A meningitis in infants and children than Group A vaccine. A patient, without malignancy and with high levels of a monoclonal antibody reactive with both Group B meningococcal and E. coli K1 capsular polysaccharides, was discovered. The specificity and protective effects of this monoclonal antibody were characterized. Its therapeutic effect in the treatment of Group B meningococcal meningitis is planned to be studied.